Last reviewed · How we verify
Hydroperoxycyclofosfamide (PERFOSFAMIDE)
Hydroperoxycyclofosfamide (generic name: PERFOSFAMIDE) is a perfosfamide drug. It is currently in Phase 2 development.
Hydroperoxycyclofosfamide works by inducing DNA crosslinks, which ultimately leads to cell death.
Hydroperoxycyclofosfamide is a small molecule with the synonyms 4-HC, 4-HYDROPEROXYCYCLOPHOSPHAMIDE, NSC-181815, PERFOSFAMIDA, PERFOSFAMIDE, and PERFOSFAMIDE.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PERFOSFAMIDE |
|---|---|
| Drug class | perfosfamide |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your DNA as a blueprint for your cells. Hydroperoxycyclofosfamide disrupts this blueprint by creating crosslinks, making it difficult for cells to function and ultimately leading to cell death. This process is a key mechanism by which perfosfamide exerts its effects.
Approved indications
Common side effects
Key clinical trials
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence (EARLY_PHASE1)
- Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma (PHASE2)
- Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma (PHASE2)
- Development of Cognitive Assessment Tools in Parkinson Disease (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroperoxycyclofosfamide CI brief — competitive landscape report
- Hydroperoxycyclofosfamide updates RSS · CI watch RSS
Frequently asked questions about Hydroperoxycyclofosfamide
What is Hydroperoxycyclofosfamide?
How does Hydroperoxycyclofosfamide work?
What is the generic name of Hydroperoxycyclofosfamide?
What drug class is Hydroperoxycyclofosfamide in?
What development phase is Hydroperoxycyclofosfamide in?
Related
- Drug class: All perfosfamide drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing